AstraZeneca’s oral breast cancer drug Truqap greenlit for NHS use
The twice daily tablet represents a significant step forward for patients with advanced breast cancer.
Therapy Area
FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer
Cingulate secures $3m to advance once-daily anxiety treatment
Tempest hits funding block for Phase III liver cancer drug-in-waiting
EC approves extension of indication for Janssen-Cilag’s Darzalex
Obesity drugs won’t be covered by Medicare under 2026 CMS policy
EC approves AstraZeneca’s Imfinzi combo for NSCLC
ABL Bio and GSK link on neurodegenerative conditions
